Survival guide to FDA inspections: Part 3, responding to observations

Survival guide to FDA inspections: Part 3, responding to observations

You survived the FDA inspection. Now what? FDA always finishes the inspection by leaving you with a list of its observation. Part 3 concludes the survival guide series by describing the steps every company should take after the inspectors leave--from developing a corrective action plan to writing a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biopharm International 2002-11, Vol.15 (11), p.42
Hauptverfasser: Lavian, Massoud, Allen, Paul W
Format: Magazinearticle
Sprache:eng
Schlagworte:
Biotechnology
Committees
Documentation
Drugs
Inspections
Investigations
Laws, regulations and rules
Manufacturing
Pharmaceutical industry
R&D
Research & development
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 11
container_start_page 42
container_title Biopharm International
container_volume 15
creator Lavian, Massoud
Allen, Paul W
description You survived the FDA inspection. Now what? FDA always finishes the inspection by leaving you with a list of its observation. Part 3 concludes the survival guide series by describing the steps every company should take after the inspectors leave--from developing a corrective action plan to writing a detailed response document.
format Magazinearticle
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_reports_195760079</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A95177625</galeid><sourcerecordid>A95177625</sourcerecordid><originalsourceid>FETCH-LOGICAL-g254t-2e368f708b6fdf1f42e9a153f5ee0d9ad590164c1d486b688864d78e1c7566073</originalsourceid><addsrcrecordid>eNptzF9LwzAUBfAiCs7pd4jvKyRt_vpW5qbCQEEF30ba3JRITWqS9fNbnW_KfTiHw497UiyIqlVJJK9O585oVRLO386Li5TeMSayVnRRbJ4PcXKTHlB_cAZQDmh72yDn0whddsGnG_SkY0b1CkVIY_DG-f6bhTZBnPSPuSzOrB4SXP3msnjdbl7W9-Xu8e5h3ezKvmI0lxXUXFqBZcutscTSCpQmrLYMABulDVOYcNoRQyVvuZSSUyMkkE4wzrGol8X18e8Yw-cBUt5HGEPMaU8UExxjoWazOppeD7B33oYcddeDh6iH4MG6eW4UI0Lwis28_IfPZ-DDdX_9F7mfZas</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>magazinearticle</recordtype><pqid>195760079</pqid></control><display><type>magazinearticle</type><title>Survival guide to FDA inspections: Part 3, responding to observations</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Lavian, Massoud ; Allen, Paul W</creator><creatorcontrib>Lavian, Massoud ; Allen, Paul W</creatorcontrib><description>You survived the FDA inspection. Now what? FDA always finishes the inspection by leaving you with a list of its observation. Part 3 concludes the survival guide series by describing the steps every company should take after the inspectors leave--from developing a corrective action plan to writing a detailed response document.</description><identifier>ISSN: 1542-166X</identifier><identifier>EISSN: 1939-1862</identifier><language>eng</language><publisher>Monmouth Junction: Intellisphere, LLC</publisher><subject>Biotechnology ; Committees ; Documentation ; Drugs ; Inspections ; Investigations ; Laws, regulations and rules ; Manufacturing ; Pharmaceutical industry ; R&amp;D ; Research &amp; development</subject><ispartof>Biopharm International, 2002-11, Vol.15 (11), p.42</ispartof><rights>COPYRIGHT 2002 Intellisphere, LLC</rights><rights>Copyright Advanstar Communications, Inc. Nov 2002</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>312,780,784,791</link.rule.ids></links><search><creatorcontrib>Lavian, Massoud</creatorcontrib><creatorcontrib>Allen, Paul W</creatorcontrib><title>Survival guide to FDA inspections: Part 3, responding to observations</title><title>Biopharm International</title><description>You survived the FDA inspection. Now what? FDA always finishes the inspection by leaving you with a list of its observation. Part 3 concludes the survival guide series by describing the steps every company should take after the inspectors leave--from developing a corrective action plan to writing a detailed response document.</description><subject>Biotechnology</subject><subject>Committees</subject><subject>Documentation</subject><subject>Drugs</subject><subject>Inspections</subject><subject>Investigations</subject><subject>Laws, regulations and rules</subject><subject>Manufacturing</subject><subject>Pharmaceutical industry</subject><subject>R&amp;D</subject><subject>Research &amp; development</subject><issn>1542-166X</issn><issn>1939-1862</issn><fulltext>true</fulltext><rsrctype>magazinearticle</rsrctype><creationdate>2002</creationdate><recordtype>magazinearticle</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptzF9LwzAUBfAiCs7pd4jvKyRt_vpW5qbCQEEF30ba3JRITWqS9fNbnW_KfTiHw497UiyIqlVJJK9O585oVRLO386Li5TeMSayVnRRbJ4PcXKTHlB_cAZQDmh72yDn0whddsGnG_SkY0b1CkVIY_DG-f6bhTZBnPSPuSzOrB4SXP3msnjdbl7W9-Xu8e5h3ezKvmI0lxXUXFqBZcutscTSCpQmrLYMABulDVOYcNoRQyVvuZSSUyMkkE4wzrGol8X18e8Yw-cBUt5HGEPMaU8UExxjoWazOppeD7B33oYcddeDh6iH4MG6eW4UI0Lwis28_IfPZ-DDdX_9F7mfZas</recordid><startdate>20021101</startdate><enddate>20021101</enddate><creator>Lavian, Massoud</creator><creator>Allen, Paul W</creator><general>Intellisphere, LLC</general><general>MultiMedia Healthcare Inc</general><scope>3V.</scope><scope>7RV</scope><scope>7WY</scope><scope>7XB</scope><scope>883</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K60</scope><scope>K6~</scope><scope>KB0</scope><scope>L.-</scope><scope>LK8</scope><scope>M0F</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>20021101</creationdate><title>Survival guide to FDA inspections: Part 3, responding to observations</title><author>Lavian, Massoud ; Allen, Paul W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g254t-2e368f708b6fdf1f42e9a153f5ee0d9ad590164c1d486b688864d78e1c7566073</frbrgroupid><rsrctype>magazinearticle</rsrctype><prefilter>magazinearticle</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Biotechnology</topic><topic>Committees</topic><topic>Documentation</topic><topic>Drugs</topic><topic>Inspections</topic><topic>Investigations</topic><topic>Laws, regulations and rules</topic><topic>Manufacturing</topic><topic>Pharmaceutical industry</topic><topic>R&amp;D</topic><topic>Research &amp; development</topic><toplevel>online_resources</toplevel><creatorcontrib>Lavian, Massoud</creatorcontrib><creatorcontrib>Allen, Paul W</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>ABI/INFORM Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Trade &amp; Industry (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ProQuest Biological Science Collection</collection><collection>ABI/INFORM Trade &amp; Industry</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Biopharm International</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lavian, Massoud</au><au>Allen, Paul W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival guide to FDA inspections: Part 3, responding to observations</atitle><jtitle>Biopharm International</jtitle><date>2002-11-01</date><risdate>2002</risdate><volume>15</volume><issue>11</issue><spage>42</spage><pages>42-</pages><issn>1542-166X</issn><eissn>1939-1862</eissn><abstract>You survived the FDA inspection. Now what? FDA always finishes the inspection by leaving you with a list of its observation. Part 3 concludes the survival guide series by describing the steps every company should take after the inspectors leave--from developing a corrective action plan to writing a detailed response document.</abstract><cop>Monmouth Junction</cop><pub>Intellisphere, LLC</pub></addata></record>
fulltext fulltext
identifier ISSN: 1542-166X
ispartof Biopharm International, 2002-11, Vol.15 (11), p.42
issn 1542-166X
1939-1862
language eng
recordid cdi_proquest_reports_195760079
source EZB-FREE-00999 freely available EZB journals
subjects Biotechnology
Committees
Documentation
Drugs
Inspections
Investigations
Laws, regulations and rules
Manufacturing
Pharmaceutical industry
R&D
Research & development
title Survival guide to FDA inspections: Part 3, responding to observations
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T13%3A32%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20guide%20to%20FDA%20inspections:%20Part%203,%20responding%20to%20observations&rft.jtitle=Biopharm%20International&rft.au=Lavian,%20Massoud&rft.date=2002-11-01&rft.volume=15&rft.issue=11&rft.spage=42&rft.pages=42-&rft.issn=1542-166X&rft.eissn=1939-1862&rft_id=info:doi/&rft_dat=%3Cgale_proqu%3EA95177625%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=195760079&rft_id=info:pmid/&rft_galeid=A95177625&rfr_iscdi=true